New daily pill shows promise for rheumatoid arthritis in early trial
NCT ID NCT07335952
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tested Proximod, a daily pill that calms the immune system, in 179 adults with moderate-to-severe rheumatoid arthritis who had not responded well to standard treatments. Participants took either 5 mg, 10 mg, or a placebo daily for three months, with one month of follow-up. The main goal was to see if Proximod could reduce joint pain and swelling better than a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Proximod (a daily pill that modulates the immune system)
What this could lead to
If it works, this could point toward a new daily treatment option for people with rheumatoid arthritis who haven't responded to standard drugs.
What could go wrong
This is an early Phase 2 trial with only 179 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chun Li
Beijing, Beijing Municipality, 100044, China
-
Guixiu Shi
Xiamen, Fujian, 361003, China
-
Hua Zhang
Zaozhuang, Shandong, 277100, China
-
Huaxiang Wu
Hangzhou, Zhejiang, 310009, China
-
Jian Wu
Suzhou, Jiangsu, 215006, China
-
Jiashun Zeng
Guiyang, Guizhou, 550004, China
-
Ling Lei
Nanning, Guangxi, 530021, China
-
Lingli Dong
Wuhan, Hubei, 430030, China
-
Mei Tian
Zunyi, Guizhou, 563099, China
-
Mingwei Deng
Guangzhou, Guangdong, China
-
Qingwen Wang
Shenzhen, Guangdong, 518036, China
-
Senhua Dai
Pingxiang, Jiangxi, 337055, China
-
Shulin Song
Yichang, Hubei, 43003, China
-
Weiqi Min
Heze, Shandong, 274006, China
-
Wubin Long
Chengdu, Sichuan, 610072, China
-
Xiaofei Shi
Luoyang, Henan, 471000, China
-
Xuebinwang
Binzhou, Shandong, 256603, China
-
Yanmei Wu
Panjin, Liaoning, 124000, China
-
Yi He
Guangzhou, Guangdong, 510630, China
-
Zili Fu
Taiyuan, Shanxi, 030001, China